{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:24:36Z","timestamp":1789878276463,"version":"4.0.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:00:00Z","timestamp":1498176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck & Co."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0178420","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T17:37:26Z","timestamp":1498239446000},"page":"e0178420","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":81,"title":["Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting"],"prefix":"10.1371","volume":"12","author":[{"given":"Amy P.","family":"Abernethy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiting","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Sorg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,6,23]]},"reference":[{"key":"ref1","article-title":"Surveillance Epidemiology and End Results (SEER) Program: SEER Cancer Statistics Review (CSR) 1975\u20132012 (updated August 20, 2015)","author":"N Howlader","year":"2015"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"RS Herbst","year":"2008","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer, 2015. http:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html<\/ext-link>"},{"key":"ref4","unstructured":"NCCN Guidelines: Non-small cell lung cancer version 7.2015, 2015. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf<\/ext-link>"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"GA Masters","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"ref6","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/annonc\/mdu199","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"M Reck","year":"2014","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"WD Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","article-title":"2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease","volume":"25","author":"B Besse","year":"2014","journal-title":"Ann Oncol"},{"issue":"33","key":"ref9","article-title":"Systemic Therapy for Stage IV Non\u00e2\u20ac\u201cSmall-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"30","author":"A. M. Gregory","journal-title":"Systemic Therapy for Stage IV Non\u00e2\u20ac\u201cSmall-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.6004\/jnccn.2012.0088","article-title":"First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions","volume":"10","author":"C Zornosa","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/lmt.13.20","article-title":"Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer","volume":"2","author":"HJ Henk","year":"2013","journal-title":"Lung Cancer Manage"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"F Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"T Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","article-title":"Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial","volume":"13","author":"L Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref15","unstructured":"Flatiron Health. http:\/\/www.flatiron.com\/life-sciences<\/ext-link>"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2217\/fon-2015-0043","article-title":"Opportunities and challenges in leveraging electronic health record data in oncology","volume":"12","author":"ML Berger","year":"2016","journal-title":"Future Oncol"},{"key":"ref17","unstructured":"Friends of Cancer Research (FOCR), Alexandria Summit. Title \u201cBlueprint for Breakthrough: Exploring the Utility of Real World Evidence (RWE), 2016\u201d Pre-meeting draft, accessed on 29-June-2016. http:\/\/www.focr.org\/sites\/default\/files\/RWE%20-%20Project%20PRE-MEETING%20DRAFT.pdf<\/ext-link>"},{"key":"ref18","unstructured":"Health Insurance Portability and Accountability Act of 1996. https:\/\/www.cms.gov\/Regulations-and-Guidance\/HIPAA-Administrative-Simplification\/HIPAAGenInfo\/Downloads\/HIPAALaw.pdf<\/ext-link>"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.6004\/jnccn.2006.0046","article-title":"Non-small cell lung cancer clinical practice guidelines in oncology","volume":"4","author":"DS Ettinger","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2014.11.002","article-title":"Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer","volume":"87","author":"KL Davis","year":"2015","journal-title":"Lung Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.lungcan.2008.05.003","article-title":"Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States","volume":"63","author":"K Lang","year":"2009","journal-title":"Lung Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.lungcan.2012.09.008","article-title":"Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network","volume":"78","author":"DP Ritzwoller","year":"2012","journal-title":"Lung Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/annonc\/mdr125","article-title":"Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy","volume":"23","author":"B Coudert","year":"2012","journal-title":"Annals of Oncology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"T Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Na\u00efve Patients With Advanced-Stage Non\u2013Small-Cell Lung Cancer","volume":"26","author":"GV Scaliotti","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1465-9921-14-139","article-title":"Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients","volume":"14","author":"N Reinmuth","year":"2013","journal-title":"Respiratory Research"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.lungcan.2015.11.011","article-title":"Non-small cell lung cancer patients with brain metastatses treated with first-line platinum-doublet chemotherapy. Analysis from the European FRAME study","volume":"90","author":"D Moro-Sibilot","year":"2015","journal-title":"Lung Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/cncr.29386","article-title":"Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: are patients undertreated?","volume":"121","author":"AG Sacher","year":"2015","journal-title":"Cancer"},{"key":"ref29","unstructured":"TARCEVA (erlotinib) Prescribing Information: Astellas Pharma US, Inc., and Genentech, Inc., 2015. http:\/\/www.gene.com\/download\/pdf\/tarceva_prescribing.pdf<\/ext-link>"},{"key":"ref30","unstructured":"ALIMPTA (pemetrexed) Prescribing Information, Revised 2\/2015: Eli Lilly and Company, 2015. http:\/\/uspl.lilly.com\/alimta\/alimta.html#pi<\/ext-link>"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0178420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T15:35:02Z","timestamp":1540049702000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0178420"}},"subtitle":[],"editor":[{"given":"Ramon Andrade","family":"de Mello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,23]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0178420","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,23]]}}}